Crossmark

Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

Crossref DOI link: https://doi.org/10.1186/s40425-019-0722-x

Published Online: 2019-09-18

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Habra, Mouhammed Amir https://orcid.org/0000-0002-4148-9637
Stephen, Bettzy

Campbell, Matthew

Hess, Kenneth

Tapia, Coya

Xu, Mingxuan

Rodon Ahnert, Jordi

Jimenez, Camilo

Lee, Jeffrey E.

Perrier, Nancy D.

Boraddus, Russell R.

Pant, Shubham

Subbiah, Vivek

Hong, David S.

Zarifa, Abdulrazzak

Fu, Siqing

Karp, Daniel D.

Meric-Bernstam, Funda

Naing, Aung
Funding

Funding for this research was provided by:

Merck Sharp and Dohme (000)

National Cancer Institute (P30CA016672)
License Information

Text and Data Mining valid from 2019-09-18
More Information

Article History

Received: 5 June 2019

Accepted: 28 August 2019

First Online: 18 September 2019

Ethics approval and consent to participate

: The University of Texas MD Anderson Cancer Center Institutional Review Board approved the study and all patients provided a written consent form to join the study.

: Not applicable.

: The authors declare that they have no competing interests.